Vector Labs Ab02245-3.0 Anti-CCL2 [CNTO 888 (Carlumab)], Mouse IgG2b, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: CNTO 888 (Carlumab)
Synonyms: MCP-1; MCP1; HC11; MCAF; C-C motif chemokine 2; monocyte chemoattractant protein 1; monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; Small-inducible cytokine A2
Amount: 200 μg
Application Codes Clone: Inhibit; Block; Therapeutic
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody specifically binds human CCL2 and does not cross react with mouse CCL2 or other human CC chemokines. It is reported that CNTO 888 recognizes a conformational epitope encompassing residues 18-24 and 45-51 that overlaps the mapped receptor binding site.
Application Notes: CCL2 is implicated in the pathogenesis of certain inflammatory diseases and cancer. Binding of CCL2 to its receptor CCR2 triggers calcium mobilization and chemotaxis. CNTO 888 is a neutralizing anti-CCL2 antibody that binds human CCL2 with high affinity of Kd=22pM and inhibits CCL2 binding to its receptor. The systemic administration of anti-CCL2 neutralizing antibodies (CNTO888 and C1142) significantly retarded tumor growth and attenuated CD68+ macrophage infiltration, which was accompanied by a significant decrease in microvascular density (PMID: 17710158). Phase 1 trials in 44 patients with solid tumors concluded that CNTO888 was well tolerated in individuals with evidence of transient free CCL2 suppression and preliminary antitumor activity (PMID: 23385782). This antibody was also capable of inhibiting growth of breast cancer when administered individually or as a cocktail (Campion et al, 2009). A phase 2 study in 46 patients with castration-resistant prostate cancer (CRPC) concluded that carlumab was well-tolerated but did not block the CCL2/CCR2 axis or show antitumor activity as a single agent in metastatic CRPC (PMID: 22907596).

Product Class:	Purified
Clone ID:	CNTO 888 (Carlumab)
Synonyms:	MCP-1; MCP1; HC11; MCAF; C-C motif chemokine 2; monocyte chemoattractant protein 1; monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; Small-inducible cytokine A2
Amount:	200 μg
Application Codes Clone:	Inhibit; Block; Therapeutic
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody specifically binds human CCL2 and does not cross react with mouse CCL2 or other human CC chemokines. It is reported that CNTO 888 recognizes a conformational epitope encompassing residues 18-24 and 45-51 that overlaps the mapped receptor binding site.
Application Notes:	CCL2 is implicated in the pathogenesis of certain inflammatory diseases and cancer. Binding of CCL2 to its receptor CCR2 triggers calcium mobilization and chemotaxis. CNTO 888 is a neutralizing anti-CCL2 antibody that binds human CCL2 with high affinity of Kd=22pM and inhibits CCL2 binding to its receptor. The systemic administration of anti-CCL2 neutralizing antibodies (CNTO888 and C1142) significantly retarded tumor growth and attenuated CD68+ macrophage infiltration, which was accompanied by a significant decrease in microvascular density (PMID: 17710158). Phase 1 trials in 44 patients with solid tumors concluded that CNTO888 was well tolerated in individuals with evidence of transient free CCL2 suppression and preliminary antitumor activity (PMID: 23385782). This antibody was also capable of inhibiting growth of breast cancer when administered individually or as a cocktail (Campion et al, 2009). A phase 2 study in 46 patients with castration-resistant prostate cancer (CRPC) concluded that carlumab was well-tolerated but did not block the CCL2/CCR2 axis or show antitumor activity as a single agent in metastatic CRPC (PMID: 22907596).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews